The global liquid biopsy market size was valued at USD 12.23 billion in 2025 and is projected to grow from USD 13.61 billion in 2026 to USD 32.11 billion by 2034, registering a CAGR of 11.32% during the forecast period from 2026 to 2034. North America dominated the liquid biopsy market with a market share of 42.15% in 2025.
Liquid biopsy is a minimally invasive diagnostic technique that analyzes biomarkers found in biological fluids, primarily blood, to detect and monitor diseases. The technique commonly examines circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), cell-free DNA (cfDNA), RNA, and extracellular vesicles released into the bloodstream. Liquid biopsy is increasingly used in cancer diagnosis and management for detecting genetic mutations, identifying treatment options, monitoring treatment response, and assessing disease progression or recurrence. The market includes liquid biopsy tests, assay kits, instruments, reagents, and related diagnostic services used in hospitals, diagnostic laboratories, research institutions, and specialized oncology centers.
Download a Free Sample To learn more about this report,
Multi-Omics and Advanced Sequencing Expand Liquid Biopsy Capabilities
The liquid biopsy market is moving beyond conventional circulating tumor DNA analysis toward multi-omics, epigenomic profiling, advanced next-generation sequencing (NGS), and bioinformatics. These technologies can provide broader information about tumor biology, including genetic alterations, gene expression, pathway activity, and treatment resistance. The development of more comprehensive assays is strengthening the role of liquid biopsy in precision oncology and enabling clinicians and researchers to obtain deeper molecular insights from small blood samples.
Liquid Biopsy Moves Toward Comprehensive and Repeatable Cancer Monitoring
Liquid biopsy is increasingly being integrated into precision oncology, treatment selection, minimal residual disease (MRD) monitoring, and disease progression assessment. Unlike tissue biopsy, blood-based testing can be repeated with relatively low patient burden, allowing clinicians to monitor molecular changes during treatment and identify emerging resistance. Increasing clinical access and the development of broader liquid biopsy panels are helping expand the technology from specialized testing toward more routine cancer management.
Growing Preference for Minimally Invasive Cancer Testing Supports Liquid Biopsy Adoption
The increasing preference for minimally invasive diagnostic procedures is supporting the adoption of liquid biopsy in cancer care. Unlike conventional tissue biopsy, liquid biopsy generally requires only a blood sample, reducing the need for invasive tissue collection and making repeat testing more practical. The ability to obtain molecular information with relatively low patient burden is particularly valuable for patients whose tumors are difficult to access or who require repeated monitoring during treatment. Growing awareness among clinicians and patients is therefore strengthening demand for blood-based cancer diagnostics.
Limited Infrastructure and Awareness Restrict Liquid Biopsy Access in Emerging Markets
The availability of liquid biopsy remains uneven across developing and underdeveloped regions because advanced sequencing platforms, specialized laboratories, trained personnel, and molecular diagnostic infrastructure can be limited. Healthcare providers may also continue relying on established tissue biopsy and imaging methods because of familiarity, availability, and reimbursement considerations. Limited awareness among patients and clinicians can further delay adoption, restricting market penetration outside developed healthcare systems.
Liquid Biopsy Creates New Avenues for Rare and Difficult-to-Diagnose Cancers
Liquid biopsy offers significant opportunities in cancers where obtaining adequate tissue samples is difficult because of tumor location, limited tumor material, or the need for repeated molecular assessment. Blood-based analysis can provide tumor-derived genetic information without requiring repeated invasive procedures, creating opportunities for earlier molecular characterization, treatment selection, and disease monitoring. As sequencing technologies become more sensitive, liquid biopsy is also gaining potential applications across cancers with limited conventional screening options.
Establishing Clinical Accuracy and Standardization Across Liquid Biopsy Tests
The liquid biopsy market faces challenges related to test sensitivity, specificity, biomarker concentrations, sample handling, analytical methods, and clinical standardization. Circulating tumor DNA and other biomarkers can occur at very low concentrations, particularly in early-stage disease, making accurate detection technically demanding. Differences in testing platforms and laboratory procedures can also affect results. Establishing consistent clinical validation, regulatory acceptance, and standardized testing protocols remains essential for broader adoption in routine cancer screening and monitoring.
The market is divided into kits and reagents, platforms and instruments, and services. The kits and reagents segment is the highest contributor to the global liquid biopsy market share, growing at a CAGR of 21.2% during the forecast period. The market for liquid biopsy kits and reagents is anticipated to grow cutting-edge products that can analyze circulating biomarkers, target enrichment, size selection, and various other tasks. The liquid biopsy instruments combine the PCR, sequencing, and real-time genetic characterization of the liquid biopsy sample under analysis. The ddPCR, produced by the American life science and clinical diagnostics company Bio-Rad Laboratories, Inc., is one illustration of such a device.
Request Customizationto receive a tailored report.
The market is divided into circulating tumor cells, circulating tumor DNA, and extracellular vesicles. The circulating tumor cell segment is the highest contributor to the market, growing at a CAGR of 21% during the forecast period. Circulating tumor cells (CTCs) are an essential diagnostic tool for comprehending the metastatic process and cancer progression. Poor survival rates are associated with CTCs in metastatic colon, prostate, and breast cancers. Individual CTCs may contain genetic information essential for understanding tumor biology and the metastatic process of a patient's tumor.
Throughout the projected period, the category with the quickest growth is anticipated to be circulating tumor DNA. The DNA from circulating tumors aids in the early detection of cancer and cancer-related mutations. It is quite effective at finding breast cancer. Consequently, it is anticipated that the increased incidence of breast cancer will accelerate the expansion of this market.
The market is divided into lung cancer, breast cancer, colorectal cancer, prostate cancer, and liver cancer. The lung cancer segment is the highest contributor to the market, growing at a CAGR of 20.4% during the forecast period. The lung cancer segment is the most significant contributor due to the high prevalence of the non-small cell lung cancer (NSCLC) type in this category, which is significantly growing globally. Further, the prostate cancer segment is anticipated to be the fastest-growing segment. This is attributed to the significantly growing prevalence of prostate cancer across the developed regions, including North America.
The market is divided into hospitals and laboratories, as well as government and academic research centers. The hospitals and laboratories segment is the highest contributor to the market, growing at a CAGR of 21.2% during the forecast period. Testing with liquid biopsies is used in hospitals and laboratories for the diagnosis, analysis, and detection of cancer. On the other hand, testing with liquid biopsies is used in government and academic research centers for research and development to understand the molecular aspects of tumors better.
Speak to an Analystto discuss market opportunities.
North America dominated the global liquid biopsy market in 2025, accounting for 42.15% of the market, with a market value of USD 5.15 billion. The regional market is projected to grow at a 11.84% CAGR during the forecast period. Growth is supported by the region's advanced healthcare infrastructure, high adoption of precision oncology, strong investment in cancer research, and increasing availability of liquid biopsy-based diagnostic tests.
The United States is a major market for liquid biopsy, supported by its advanced cancer diagnostic infrastructure, strong research ecosystem, and growing adoption of precision medicine. Increasing use of circulating tumor DNA testing for treatment selection, therapy monitoring, and detection of minimal residual disease is supporting market growth.
Canada's liquid biopsy market is supported by increasing cancer research activities, growing adoption of precision medicine, and improvements in molecular diagnostic capabilities. Healthcare institutions and research organizations are increasingly evaluating liquid biopsy for cancer detection, treatment monitoring, and genomic profiling.
Unlock Regional Insightsto access country-level data, & regional trends.
Europe accounted for 28.34% of the global liquid biopsy market in 2025, with a market value of USD 3.47 billion. The regional market is expected to grow at a 14.62% CAGR during the forecast period. Growth is supported by increasing adoption of precision oncology, expanding molecular diagnostic capabilities, and rising investment in cancer research.
Germany's liquid biopsy market is supported by its advanced healthcare infrastructure, strong oncology research capabilities, and growing emphasis on personalized medicine. Increasing adoption of genomic profiling and molecular diagnostics is creating demand for blood-based testing technologies. Research into circulating tumor DNA and other biomarkers is also expanding the potential applications of liquid biopsy in cancer treatment monitoring and therapy selection.
The United Kingdom's liquid biopsy market is driven by strong cancer research programs, increasing adoption of precision medicine, and the development of advanced molecular diagnostics. Healthcare providers and research institutions are increasingly evaluating liquid biopsy for treatment selection, disease monitoring, and detection of residual disease.
Asia Pacific represented 21.18% of the global liquid biopsy market in 2025, with a market value of USD 2.59 billion. The regional market is projected to grow at a 13.91% CAGR. Growth is driven by rising cancer incidence, improving healthcare infrastructure, increasing investment in molecular diagnostics, and growing awareness of minimally invasive cancer testing.
Japan's liquid biopsy market is supported by its advanced healthcare system, strong cancer research capabilities, and growing focus on precision medicine. Increasing research into circulating tumor DNA and other cancer biomarkers is encouraging the development of blood-based diagnostic applications. The country's aging population and growing need for efficient cancer diagnosis and monitoring are also supporting demand for minimally invasive testing technologies.
China's liquid biopsy market is expanding alongside its rapidly developing healthcare and biotechnology sectors. Rising cancer burden, increasing investment in genomic medicine, and improvements in molecular diagnostic infrastructure are supporting demand for liquid biopsy technologies. The expansion of precision oncology and growing availability of next-generation sequencing are further creating opportunities for blood-based cancer testing.
Latin America accounted for 4.62% of the global liquid biopsy market in 2025, with a market value of USD 0.57 billion. The regional market is expected to grow at a 10.74% CAGR during the forecast period. Growth is supported by increasing cancer incidence, improving access to molecular diagnostics, and growing awareness of minimally invasive testing methods.
Brazil is an important market for liquid biopsy in Latin America, supported by its large healthcare system and growing focus on cancer diagnostics. Increasing cancer research, adoption of molecular testing, and demand for personalized treatment are creating opportunities for liquid biopsy technologies. Improvements in diagnostic infrastructure and growing awareness of minimally invasive cancer testing are expected to further support market expansion.
The Middle East and Africa accounted for 3.71% of the global liquid biopsy market in 2025, with a market value of USD 0.45 billion. The regional market is projected to grow at a 9.88% CAGR. Growth is supported by improving healthcare infrastructure, increasing cancer awareness, and rising investment in advanced diagnostic technologies.
The UAE's liquid biopsy market is supported by its advanced healthcare infrastructure, growing oncology capabilities, and increasing investment in precision medicine. The country's development as a regional healthcare and medical research hub is encouraging the adoption of advanced molecular diagnostic technologies. Growing demand for early cancer detection, genomic profiling, and minimally invasive monitoring is expected to support liquid biopsy market growth.
The liquid biopsy market is highly competitive, with companies focusing on next-generation sequencing, circulating tumor DNA analysis, comprehensive genomic profiling, molecular diagnostics, and minimal residual disease testing. Key market participants include Bio-Rad Laboratories Inc., Biocept Inc., Guardant Health Inc., Illumina Inc., Hoffmann-La Roche Ltd. (Foundation Medicine Inc.), Johnson & Johnson, Laboratory Corporation of America Holdings, MDxHealth SA, QIAGEN N.V., and Thermo Fisher Scientific Inc. Companies are strengthening their positions through advanced sequencing platforms, broader biomarker panels, clinical validation, and partnerships aimed at expanding access to precision oncology.
Illumina Inc. is a major participant in the liquid biopsy market, leveraging its next-generation sequencing (NGS) platforms and comprehensive genomic profiling technologies for circulating tumor DNA analysis. The company's portfolio supports research and clinical applications involving ctDNA, cell-free DNA, circulating tumor cells, and other cancer biomarkers. Illumina's sequencing technologies enable researchers and healthcare providers to analyze multiple genomic alterations from blood samples, supporting applications such as treatment selection, clinical trial matching, and disease monitoring.
Customize This Report to Match Your Strategic Objectives
Author's Details
Healthcare Lead
Debashree Bora is a strategic healthcare research professional with nearly eight years of hands on experience in market intelligence, encompassing primary research, secondary research, market estimation, and consulting engagements. She specializes in pharmaceutical, biotechnology, medical devices, healthcare services, clinical trials, and healthcare outsourcing sectors, providing actionable insights on evolving industry trends, regulatory landscapes, competitive dynamics, and market opportunities. Debashree’s research helps global clients evaluate market potential, identify growth opportunities, strengthen commercial strategies, and make informed business decisions.
Bovine Serum Market Size, Share, Growth, Analysis, Report, 2034
Asia Pacific TB Diagnostics Market Size, Share & Growth Graph by 2034
South Korea Epigenetics Market Size, Supply & Growth Report 2034
Europe Tangential Flow Filtration Market Size, Share & Trends | Industry Report, 2034
Asia Pacific Genetic Testing Market Size, 2034
North America TB Diagnostics Market Size & Trends Analysis, 2034
We are featured on:
sales@straitsresearch.com